OpenAI Backs Sam Altman's Merge Labs in $252 Million Push for Non-Invasive Brain-Computer Interfaces, Challenging Neuralink's Dominance

Spread the Message

Read Time:3 Minute, 57 Second

OpenAI has invested in Merge Labs, a brain-computer interface (BCI) startup co-founded by its CEO Sam Altman, as part of a $252 million seed round that emerged from stealth mode this week. The funding, which positions Merge Labs at an $850 million valuation, aims to develop safe, high-bandwidth, non-invasive BCIs using innovative approaches like ultrasound and molecular interfaces to connect human brains directly with AI systems. Announced on January 14, 2026, this move intensifies competition in the BCI space against Elon Musk’s Neuralink and signals a shift toward consumer-accessible neural tech.

Key Developments in Merge Labs’ Technology

Merge Labs focuses on bridging biological and artificial intelligence to enhance human capabilities through non-invasive methods, avoiding the surgical implants required by rivals like Neuralink. The startup plans to use “entirely new technologies that connect with neurons using molecules instead of electrodes” and deep-reaching modalities like ultrasound, combined with AI to interpret neural signals at higher bandwidths. Early prototypes emphasize advanced sensors and machine learning for translating brain activity into digital commands, with OpenAI providing custom AI models to handle noisy signals.

Unlike Neuralink’s electrode-based implants, which involve a robot inserting flexible threads into the brain, Merge Labs prioritizes safety and scalability for broader applications beyond medical use. The company emerged from stealth with backing from investors like Bain Capital and Valve co-founder Gabe Newell, underscoring industry confidence in its vision. OpenAI stated, “We are excited to support and collaborate with Merge Labs as they turn an ambitious idea into reality and ultimately products that are useful for people.”

Comparing Merge Labs and Neuralink Approaches

Aspect	Merge Labs	Neuralink
Invasiveness	Non-invasive (ultrasound, molecules)	Invasive (surgical electrode implants)
Funding (Recent)	$252M seed at $850M valuation	$600M at $9B valuation
Technology Focus	AI-integrated, high-bandwidth neural reading	Thought-controlled devices for paralysis
Stage	Early research, pre-clinical	Human trials ongoing since 2024
Key Challenges	Signal accuracy in non-invasive methods	Wire retraction, immune response

Merge Labs differentiates itself by targeting “AI operating systems that can interpret intent” from limited signals, potentially enabling everyday human-AI interaction without surgery.

Medical Applications and Potential Impact

BCIs like those from Merge Labs hold promise for patients with paralysis, stroke, or neurological disorders, enabling thought-based control of devices to restore communication and mobility. Non-invasive ultrasound BCIs could improve upper limb function and quality of life in stroke patients, particularly in subacute phases, with studies showing good safety profiles. For instance, functional ultrasound offers high spatiotemporal resolution (100 μm, 1 ms) for neural signal reading without tissue damage, outperforming EEG’s low spatial resolution.

In public health, scalable BCIs could reduce burdens on rehabilitation services; Neuralink’s trials already allow quadriplegic patients to control cursors via thought. Merge Labs’ consumer focus might extend to productivity tools, but medical validation remains key, with plans starting in clinical trials for needy patients.

Expert Perspectives and Balanced Viewpoints

Experts praise the non-invasive push but urge caution. Caltech professor David Shapiro, Merge Labs co-founder, noted, “We can build brain computer interfaces that can interface with many more neurons… in a form factor that is much less invasive,” aiming for mass accessibility. Dr. Leigh R. Hochberg of BrainGate highlighted low adverse event rates in long-term BCI trials, supporting further evaluation for paralysis restoration.

Critics point to limitations: non-invasive tech like ultrasound faces signal-to-noise challenges and lower bandwidth than invasives, potentially delaying real-world use. Neuralink has encountered wire retraction and FDA safety concerns, yet advanced to human implants. Ethical experts warn of privacy risks, hacking vulnerabilities, inequality in access, and consent issues in cognitive enhancement.

Broader Implications and Future Outlook

This investment tightens OpenAI’s hardware-software loop, potentially enabling “thought-to-ChatGPT” interactions, but raises governance questions over Altman’s dual roles. Public health benefits include democratizing neural rehab, yet equitable access is crucial to avoid stratification. Regulatory success will determine leadership; well-funded entrants like Merge Labs accelerate adoption.

Limitations persist: long-term safety data is scarce for novel methods, and multicenter trials are needed. As BCIs evolve, balancing innovation with ethics ensures responsible progress.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References: